Predicting Speech Intelligibility Based on Spatial Tongue-Jaw Coupling in Persons With Amyotrophic Lateral Sclerosis: The Impact of Tongue Weakness and Jaw Adaptation.

Purpose Motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), have a devastating effect on speech muscle function that often results in severe communication deficits. Over the course of bulbar disease, tongue and jaw movements are modified, but their impact on speech is poorly understood. The aim of this study was to determine the effect of disease-related changes in tongue-jaw movement coupling on speech intelligibility in persons at different stages of bulbar ALS. Method Parallel factor analysis was used to quantify the pattern of spatial coupling between 4 semi-independent regions of the tongue and the jaw in various vowels and consonants in 10 individuals with ALS and 10 healthy individuals, respectively, from the X-Ray Microbeam database (Westbury, 1994). The relation of spatial tongue-jaw coupling to speech intelligibility was examined in individuals at the early and late stages of bulbar ALS and healthy individuals. Results Tongue movement, independent of the jaw, decreased early and progressively, which negatively impacted speech intelligibility. Jaw contribution to tongue movement was increased during the early stages of bulbar ALS compared to that of the healthy subjects, which was followed by a decrease during the late stages of bulbar ALS. The early-stage increase of jaw contribution significantly improved speech intelligibility and is thus most likely to be an adaptive strategy to mitigate the negative impact of tongue movement reductions on speech intelligibility. This adaptive strategy became unavailable during the late stages of bulbar ALS, which might accelerate intelligibility decline. Conclusions The loss of functional tongue-jaw coupling may be the critical physiological factor leading to the eventual loss of functional speech in ALS. Monitoring changes in tongue-jaw coupling may improve the prediction about the timing of speech loss and guide clinical management of dysarthria in ALS.